
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc's clinical-stage programs, particularly GRI-0621 and GRI-0803, showcase promising data, with interim results indicating improvements in lung function and serum biomarkers, suggesting efficacy in addressing fibrotic and autoimmune disorders. The company's current valuation appears attractive, with significant upside potential based on a net present value (NPV) analysis, reflecting the results of their ongoing clinical trials. Positive interim data along with a well-tolerated treatment regimen further bolster the prospects for growth, highlighting GRI Bio's potential in the biotech sector.
Bears say
GRI Bio Inc. reported a net loss of $3.4 million for the recent quarter, with an earnings per share (EPS) of $(1.28), which was worse than both the analyst estimates and consensus expectations. The company faces significant risks, including balance sheet and liquidity challenges, the potential failure of its product candidates in clinical trials, and the need to secure regulatory approvals and reimbursement, all of which could hinder its ability to commercialize its therapies successfully. Despite the potential for substantial market opportunities, the long development timelines and high risks associated with clinical and commercial failures contribute to a negative financial outlook for the company's stock.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares